Literature DB >> 30723039

Challenges in anticancer drug R&D in China.

Shen Zhao1, Cheng Lv2, Jifang Gong3, Fang Wenfeng1, Xichun Hu4, Yi Ba5, Chen Xiaoyuan6, Yang Zhimin6, Lin Shen3, Li Zhang7.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 30723039     DOI： 10.1016/S1470-2045(18)30865-9

Source DB:  PubMed          Journal:  Lancet Oncol        ISSN： 1470-2045            Impact factor:   41.316


× No keyword cloud information.
  3 in total

1.  Anticancer drug R&D landscape in China.

Authors:  Shen Zhao; Hongyun Zhao; Cheng Lv; Jifang Gong; Jian Zhang; Wenfeng Fang; Jin Li; Xichun Hu; Yi Ba; Binghe Xu; Yanqiao Zhang; Yun Fan; Kunyan Li; Xiaoyuan Chen; Zhimin Yang; Lin Shen; Li Zhang
Journal:  J Hematol Oncol       Date:  2020-05-13       Impact factor: 17.388

Review 2.  Changes in clinical trials of endocrine disorder and metabolism and nutrition disorder drugs in mainland China over 2010-2019.

Authors:  Xin Liu; Suqin Wu; Jian Sun; Suiqin Ni; Laichun Lu; Wei Hu; Hua Wei; Yanqin Zou; Ting Li; Jintong Li; Bugela Mijiti; PingFei Fang; Limei Zhao; Huan Zhou; Xiaoming Xing; Haitao Niu; Yu Cao
Journal:  Pharmacol Res Perspect       Date:  2021-04

3.  Overall Survival Benefits of Cancer Drugs Approved in China From 2005 to 2020.

Authors:  Yichen Zhang; Huseyin Naci; Anita K Wagner; Ziyue Xu; Yu Yang; Jun Zhu; Jiafu Ji; Luwen Shi; Xiaodong Guan
Journal:  JAMA Netw Open       Date:  2022-08-01
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.